CEP
UTHR icon

Chicago Equity Partners’s United Therapeutics UTHR Stock Holding History

Chicago Equity Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$2.31M Buy
24,415
+1,290
+6% +$123K 0.23% 112
2019
Q4 		$2.04M Buy
+23,125
New +$2.03M 0.12% 264
2019
Q2 		– Sell
-11,880
Closed -$1.39M – 978
2019
Q1 		$1.39M Sell
11,880
-3,705
-24% -$432K 0.05% 427
2018
Q4 		$1.7M Sell
15,585
-975
-6% -$113K 0.07% 372
2018
Q3 		$2.12M Sell
16,560
-2,535
-13% -$314K 0.06% 362
2018
Q2 		$2.16M Sell
19,095
-23,460
-55% -$2.58M 0.07% 373
2018
Q1 		$4.78M Sell
42,555
-2,675
-6% -$340K 0.15% 189
2017
Q4 		$6.69M Sell
45,230
-4,130
-8% -$525K 0.2% 149
2017
Q3 		$5.78M Sell
49,360
-14,955
-23% -$1.91M 0.18% 163
2017
Q2 		$8.34M Sell
64,315
-990
-2% -$124K 0.23% 130
2017
Q1 		$8.84M Sell
65,305
-4,555
-7% -$690K 0.25% 107
2016
Q4 		$10M Sell
69,860
-21,700
-24% -$2.77M 0.27% 100
2016
Q3 		$10.8M Sell
91,560
-1,535
-2% -$184K 0.3% 93
2016
Q2 		$9.86M Sell
93,095
-110,155
-54% -$12.3M 0.29% 98
2016
Q1 		$22.6M Buy
203,250
+59,335
+41% +$7.51M 0.66% 38
2015
Q4 		$22.5M Buy
143,915
+32,460
+29% +$4.73M 0.6% 52
2015
Q3 		$14.6M Sell
111,455
-9,740
-8% -$1.56M 0.41% 83
2015
Q2 		$21.1M Sell
121,195
-12,710
-9% -$2.29M 0.57% 61
2015
Q1 		$23.1M Sell
133,905
-2,510
-2% -$383K 0.62% 59
2014
Q4 		$17.7M Sell
136,415
-84,890
-38% -$10.9M 0.48% 70
2014
Q3 		$28.5M Sell
221,305
-8,660
-4% -$893K 0.75% 40
2014
Q2 		$20.3M Buy
229,965
+85,805
+60% +$8.25M 0.54% 68
2014
Q1 		$13.6M Buy
144,160
+19,590
+16% +$2M 0.37% 93
2013
Q4 		$14.1M Buy
124,570
+14,660
+13% +$1.32M 0.42% 87
2013
Q3 		$8.67M Sell
109,910
-13,840
-11% -$1.01M 0.27% 107
2013
Q2 		$8.14M Buy
+123,750
New +$7.97M 0.25% 107

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Chicago Equity Partners's UTHR Position: Q1 2020 in Review

Chicago Equity Partners increased its United Therapeutics (UTHR) stake by 5.6% in Q1 2020, buying an estimated $123K and bringing the position to 24,415 shares worth $2.31M. The position accounts for 0.23% of the portfolio, ranked #112.

Chicago Equity Partners first reported a position in UTHR in Q2 2013 and has held it in 26 quarters since. The position peaked at $28.5M in Q3 2014. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

  • Chicago Equity Partners held 24,415 shares of United Therapeutics worth $2.31M as of Q1 2020.
  • Chicago Equity Partners bought 1,290 United Therapeutics shares in Q1 2020, an estimated $123K.
  • United Therapeutics made up 0.23% of Chicago Equity Partners's portfolio in Q1 2020, its #112 holding.
  • Chicago Equity Partners first reported a position in United Therapeutics in Q2 2013 and has held it in 26 quarters since.
  • Chicago Equity Partners's United Therapeutics position peaked at $28.5M in Q3 2014.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.